Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07805369) titled 'A Phase 1 Study of DEM301 in Participants With Metastatic Colorectal Cancer' on Sept. 1.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: DEM BioPharma, Inc.
Condition:
Metastatic Colorectal Cancer
Colon Cancer
Rectal Cancer
Intervention:
Drug: DEM301
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: September 2026
Target Sample Size: 60
To know more, visit https://clinicaltrials.gov/study/NCT07805369
Disclaimer: Curated by HT Syndication....